Carsten Bergmann

Current Position

Group Leader

Academic Education

1993 - 2000

M.D., Medicine, Medical School RWTH Aachen University

Advanced Qualifications

2010	Adjunct Professor of Human Genetics, RWTH Aachen University, Department of Human Genetics
2006	Habilitation, Human Genetics, Clinical and molecular characterization of polycystic kidney disease, RWTH Aachen University, Department of Human Genetics

Postgraduate Positions

2019 - present	Medical and Managing Director Genetics Global, Limbach Genetics and Medizinische Genetik Mainz
2012 - present	Group Leader, Center for Clinical Research, Medical Center - University of Freiburg
2015-2019	Director of Genetics Europe, Sonic Healthcare
2009 - 2019	Head and Medical Director, Bioscientia, Human Genetics
2005 - 2009	Group leader and resident/consultant, RWTH Aachen University, Department of Human Genetics
2004 - 2005	Resident, RWTH Aachen University, Department of Pediatrics
2000 - 2004	Group Leader and Resident, RWTH Aachen University, Department of Human Genetics

Link to all publications of Carsten Bergmann: PubMed

Publications on CRC 1453 funding

de Fallois J, Sieckmann T, Schönauer R, …, Bergmann C, …, Kirschner KM, Shril S, Hildebrandt F, Chung WK, Halbritter J. Pathogenic PHIP Variants are Variably Associated With CAKUT. Kidney Int Rep (2024). Czogalla J, Schliffke S, Lu S, Schwerk M, Petereit H, …, Bergmann C, Benzing T, Wiech T, Puelles VG, Huber TB. Ibrutinib-associated focal segmental glomerulosclerosis and the impact of podocin mutations in chronic lymphocytic leukemia. Kidney Int (2024). Riedhammer KM, Nguyen TMT, Kosukcu C, Calzada-Wack J, Li Y, …, Schlosser P, …, Wuttke M, …, Bergmann C, …, Antony D, …, Schell C, …, Köttgen A, Arnold S, Ozaltin F, Schmidts M, Hoefele J. Implication of transcription factor FOXD2 dysfunction in syndromic congenital anomalies of the kidney and urinary tract (CAKUT). Kidney Int (2023). Schönauer R, Sierks D, Boerrigter M, Jawaid T, Caroff L, …, Bergmann C, …, Harris PC, Drenth JPH, Halbritter J. Sex, Genotype, and Liver Volume Progression as Risk of Hospitalization Determinants in Autosomal Dominant Polycystic Liver Disease. Gastroenterology (2023). Riedmann H, Kayser S, Helmstädter M, Epting D, Bergmann C. Kif21a deficiency leads to impaired glomerular filtration barrier function. Sci Rep (2023). Ott E, Hoff S, Indorf L, Ditengou FA, Müller J, …, Kramer-Zucker A, Bergmann C, Epting D. A novel role for the chloride intracellular channel protein Clic5 in ciliary function. Sci Rep (2023). Schlevogt B, Schlieper V, Krader J, Schröter R, Wagner T, …, Bergmann C, Nedvetsky PI, Krahn MP. A SEC61A1 variant is associated with autosomal dominant polycystic liver disease. Liver Int (2022). Sierks D, Schönauer R, Friedrich A, Hantmann E, de Fallois J, …, Bergmann C, Berg T, Halbritter J. Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis. JHEP Rep (2022). Aypek H, Krisp C, Lu S, Liu S, Kylies D, …, Bergmann C, Huber TB, Grahammer F. Loss of the collagen IV modifier prolyl 3-hydroxylase 2 causes thin basement membrane nephropathy. J Clin Invest (2022). Münch J, Engesser M, Schönauer R, Hamm JA, Hartig C, …, Bergmann C, …, Lo CW, Popp B, Halbritter J. Biallelic pathogenic variants in roundabout guidance receptor 1 associate with syndromic congenital anomalies of the kidney and urinary tract. Kidney Int (2022). KDIGO Conference Participants. Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int (2022). Devane J, Ott E, Olinger EG, Epting D, Decker E, …, Börries M, Metzger P, Schell C, …, Schlevogt B, Sayer JA, Bergmann C. Progressive liver, kidney, and heart degeneration in children and adults affected by TULP3 mutations. Am J Hum Genet (2022). Ziegler WH, Lüdiger S, Hassan F, Georgiadis ME, Swolana K, …, Bergmann C, Soetje B, Haffner D. Primary URECs: a source to better understand the pathology of renal tubular epithelia in pediatric hereditary cystic kidney diseases. Orphanet J Rare Dis (2022). Epting D, Decker E, Ott E, Eisenberger T, Bader I, Bachmann N, Bergmann C. The ciliary transition zone protein TMEM218 synergistically interacts with the NPHP module and its reduced dosage leads to a wide range of syndromic ciliopathies. Hum Mol Genet (2022). Choi M, Rübsam A, Schulz M, Decker E, Friedrich A, Schrezenmeier E, Halleck F, Eckardt KU, Bergmann C. Interstitial Nephritis: A Change in Diagnosis With Next-Generation Sequencing. Kidney Int Rep (2022). Boeckhaus J, Hoefele J, Riedhammer KM, Nagel M, Beck BB, …, Bergmann C, …, Troesch V, Stock J, Gross O. Lifelong effect of therapy in young patients with the COL4A5 Alport missense variant p.(Gly624Asp): a prospective cohort study. Nephrol Dial Transplant (2022). Mohamed M, Tellez J, Bergmann C, Gale DP, Sayer JA, Olinger E. Pseudodominant Alport syndrome caused by pathogenic homozygous and compound heterozygous COL4A3 splicing variants. Ann Hum Genet (2022). Knoers N, Antignac C, Bergmann C, Dahan K, Giglio S, …, Remuzzi G, Vargas-Poussou R, Schaefer F. Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice. Nephrol Dial Transplant (2021). Schrezenmeier E, Kremerskothen E, Halleck F, Staeck O, Liefeldt L, …, Wagner T, Budde K, Bergmann C. The underestimated burden of monogenic kidney disease in adults waitlisted for kidney transplantation. Genet Med (2021). Gimpel C, Bergmann C, Mekahli D. The wind of change in the management of autosomal dominant polycystic kidney disease in childhood. Pediatr Nephrol (2021). Raina R, Chakraborty R, Sethi SK, Kumar D, Gibson K, Bergmann C. Diagnosis and Management of Renal Cystic Disease of the Newborn: Core Curriculum 2021. Am J Kidney Dis (2021). Pokidysheva EN, Seeger H, Pedchenko V, Chetyrkin S, Bergmann C, …, Boudko SP, Kistler AD, Hudson BG. Collagen IVα345 dysfunction in glomerular basement membrane diseases. I. Discovery of a COL4A3 variant in familial Goodpasture’s and Alport diseases. J Biol Chem (2021).